title: Adiponectin in relation to insulin sensitivity and insulin secretion in the development of type 2 diabetes: a prospective study in 64-year-old women.
abstract: OBJECTIVE
  To examine how serum adiponectin levels predict the incidence of type 2 diabetes, from different prediabetic states, in relation to insulin sensitivity and β-cell function during 5.5 years of follow-up.
  
  
  METHODS
  In a population-based cohort of 64-year-old Caucasian women, we assessed glucose tolerance, insulin sensitivity as homeostasis model assessment, insulin secretion as acute insulin response, lifestyle factors and serum concentrations of adiponectin and high-sensitivity C-reactive protein. After 5.5 years of follow-up, 167 women with normal glucose tolerance (NGT) and 174 with impaired glucose tolerance (IGT) at baseline were re-examined and incidence of diabetes was assessed.
  
  
  RESULTS
  A total of 69 new cases of diabetes were detected during follow-up. Diabetes incidence was independently predicted by low levels of serum adiponectin, insulin resistance and insulin secretion, cigarette smoking, impaired fasting glucose (IFG) and IGT at baseline. Serum adiponectin below 11.54 g L(-1) was associated with an odds ratio of 3.6 (95% confidence interval 1.4-8.6) for future type 2 diabetes. At baseline, a high serum adiponectin concentration correlated positively with high levels of insulin sensitivity and insulin secretion. Women with incident diabetes had lower serum adiponectin levels in the NGT, IFG and IGT groups at baseline compared to those who did not develop diabetes during follow-up.
  
  
  CONCLUSIONS
  Low adiponectin concentrations were associated with future diabetes independently of insulin secretion and sensitivity, as well as IGT, IFG, smoking and abdominal obesity.
authors.affiliation: Wallenberg Laboratory for Cardiovascular Research at the Center for Cardiovascular and Metabolic Research, Institute of Medicine, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden. bjorn.fagerberg@wlab.gu.se
authors.forename: B
authors.initials: B
authors.lastname: Fagerberg
authors.forename: D
authors.initials: D
authors.lastname: Kellis
authors.forename: G
authors.initials: G
authors.lastname: Bergström
authors.forename: C J
authors.initials: CJ
authors.lastname: Behre
mesh_terms: D052242:Adiponectin / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000503:physiopathology; D018450:Disease Progression; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D007333:Insulin Resistance / Q000502:physiology*; D000078790:Insulin Secretion; D008875:Middle Aged; D011236:Prediabetic State / Q000097:blood* / Q000503:physiopathology; D011379:Prognosis
chemical_list: D052242:Adiponectin; D015415:Biomarkers; D007328:Insulin